The AABB Chagas Biovigilance Network platform was established to collect, report and analyze screening and confirmatory results from the testing of blood donors for antibodies to Trypanosoma cruzi. The platform was discontinued on February 14, 2020. A letter to the Chagas Biovigilance Network participants describes the details.
Data was downloaded on 12/20/2019.
For questions, please contact us at hemovigilance@aabb.org.
Click
the map above to view full interactive data
The data posted on this Web site is provided by third parties and is not verified by AABB. Accordingly, AABB makes no guarantee or promise that the data is current, valid, or accurate. No content on this site is intended to constitute professional advice, whether medical, legal or otherwise. AABB expressly disclaims any liability or loss that may arise either directly or indirectly from relying on the information, services or other material on this site.
Reporting facilities that are HIPAA-compliant should report only patient data that has been de-identified in accordance with HIPAA de-identification standards. AABB is not responsible for reporting facilities’ compliance with federal, state or local laws or regulations.
AABB Publishes Updated Fact Sheets Highlighting Emerging Threats to Blood Safety
February 28, 2024
FDA Releases 2021 Report on Fatalities Following Blood Collection and Transfusion
September 29, 2023
AABB Donor Reaction Severity Grading Tool Validated in New Study
September 20, 2023